Method for the determination of liability in human individuals to develop atherosclerosis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 18, 1986
Grant Date -
N/A
app pub date -
Feb 18, 1983
filing date -
Mar 3, 1982
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Liability in human individuals to develop non-insulin-dependent diabetes mellitus (NIDDM) and/or atherosclerosis is determined by restriction enzyme mapping of DNA from a human individual using a probe selected from the group consisting of (i) cDNA complementary to the mRNA coding for the human insulin, (ii) human genomic DNA containing the actual insulin gene, (iii) DNA sequences of human genomic DNA located within 20.times.10.sup.6 base pairs from the insulin gene in either direction, and examining the distribution of DNA fragments for the appearance of insertion sequences of approximately 1600 to 2300 base pairs (U alleles) the occurrence of which indicates a liability for said individual to develop elevated blood glucose concentrations and/or atherosclerosis and in homozygous form a liability to develop NIDDM.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully